Journal article
Ga-68-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer
Amy Davies, Marcus Foo, Chun Loo Gan, John Kourambas, Nicholas Redgrave, Scott Donnellan, Sree Appu, Scott Williams, Andrew Coleman, Eva Segelov, Jason Bradley, Geoffrey Soo, Shakher Ramdave, Edmond M Kwan, Arun A Azad
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY | Published : 2022
DOI: 10.1111/ajco.13595
Abstract
Objective: PSMA PET/CT has demonstrated superior sensitivity over conventional imaging in the detection of local and distant recurrence in biochemically relapsed (BCR) prostate cancer. We prospectively investigated the management impact of 68Ga-PSMA PET/CT imaging in men with BCR, with the aim of identifying baseline clinicopathological predictors for management change. Patients and methods: Men with BCR who met eligibility criteria underwent 68Ga-PSMA-11 PET/CT at Monash Health (Melbourne, Australia). Intended management plans were prospectively documented before and after 68Ga-PSMA PET/CT imaging. Binary logistic regression analysis was performed to identify potential clinicopathological p..
View full abstractGrants
Funding Acknowledgements
AstraZeneca provided funding support for <SUP>68</SUP>Ga-PSMA-11 PET/CT image acquisition.